Novo Nordisk A/ S stock (DK0060534915): GLP-1 momentum after latest obesity data and U.S. pricing headlines

Novo Nordisk A/S remains in the spotlight as fresh data on its obesity drugs and ongoing U.S. pricing discussions shape expectations for revenue growth and margins, while investors assess what the next phase of GLP-1 demand could look like.

Novo Nordisk A/S stayed in focus recently as investors digested new clinical and real?world data around its obesity treatments Wegovy and Ozempic, as well as ongoing headlines about U.S. drug pricing and access. The company has become one of the most valuable healthcare names globally on the back of demand for GLP?1 medicines, according to multiple earnings and regulatory updates published in 2024 by Novo Nordisk and major business media.

In early May 2025, Novo Nordisk said that additional analyses from its SELECT cardiovascular outcomes trial with Wegovy supported the potential of obesity treatment to reduce the risk of serious heart events in people with overweight and obesity, according to Novo Nordisk press materials as of 05/06/2025. The SELECT trial had first shown a significant reduction in major adverse cardiovascular events in 2023, and follow?up data continue to be a key pillar in payer and physician discussions.

Separately, U.S. policy makers and insurers have continued to debate how to cover obesity drugs in Medicare and commercial plans, with GLP?1 pricing mentioned in several congressional and health policy hearings in 2024, according to Reuters healthcare coverage as of 10/15/2024. For Novo Nordisk, these debates matter because the United States is the largest single market for its diabetes and obesity treatments and a core driver of group profitability.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk
• Sector/industry: Pharmaceuticals, diabetes and obesity care
• Headquarters/country: Bagsværd, Denmark
• Core markets: United States, Europe, selected international markets
• Key revenue drivers: GLP?1 medicines for diabetes and obesity, insulin portfolio, rare disease therapies
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NOVO?B); U.S. ADR listing on NYSE (ticker: NVO)
• Trading currency: Danish krone in Copenhagen; U.S. dollar for NYSE ADR

Novo Nordisk A/S: core business model

Novo Nordisk is a global healthcare group focused on treatments for diabetes, obesity and rare diseases such as hemophilia and growth disorders. The company’s history in insulin goes back a century, and it has built a vertically integrated model that covers research, development, manufacturing and global commercialization of its medicines, according to corporate materials and annual reports published in 2024 by Novo Nordisk.

The company generates the bulk of its revenue from chronic therapies that patients take for years, often administered via injectable pens or, more recently, oral formulations. That recurring revenue base gives Novo Nordisk relatively high visibility on its medium?term cash flows, but it also exposes the group to reimbursement dynamics and competition from other large pharmaceutical companies that develop similar drugs, as described in investor presentations released in 2024 by Novo Nordisk.

Novo Nordisk organizes its business mainly around two large areas: Diabetes & Obesity Care and Rare Disease. The Diabetes & Obesity franchise includes GLP?1 products such as Ozempic for type 2 diabetes and Wegovy for obesity, as well as insulins and other related medicines. The Rare Disease segment focuses on treatments for bleeding disorders and other niche indications, which typically carry higher prices but address smaller patient populations.

From a strategic standpoint, Novo Nordisk invests heavily in research and development to extend the GLP?1 class and explore complementary mechanisms that could improve weight loss or metabolic control. It also spends significant capital on expanding manufacturing capacity, particularly for injectable pens and fill?finish facilities, to keep up with demand for its once?weekly GLP?1 therapies, according to Novo Nordisk news materials as of 11/14/2024.

Main revenue and product drivers for Novo Nordisk A/S

The clearest revenue growth driver for Novo Nordisk in recent years has been the GLP?1 franchise. Ozempic, originally approved for type 2 diabetes, and Wegovy, marketed for chronic weight management, have both seen rapid uptake in the United States and other markets. Demand has at times exceeded supply, leading to intermittent drug shortages and prioritization of certain dose strengths, according to updates from regulators and company statements throughout 2024 reported by Reuters as of 09/05/2024.

In its full?year 2024 report, published in early 2025, Novo Nordisk highlighted strong double?digit sales growth in GLP?1 therapies for both diabetes and obesity, while some older insulin products showed more modest trends due to price pressure and competition. The company also noted rising investments in capacity expansion to support future demand for obesity treatments, according to Novo Nordisk’s 2024 annual reporting and accompanying investor materials released in early 2025.

Another revenue driver is the company’s push into oral GLP?1 formulations. Rybelsus, an oral semaglutide tablet for type 2 diabetes, gives Novo Nordisk an entry point for patients who prefer not to start with injections. While still smaller in scale than injectable Ozempic, the oral option broadens the addressable market and could help defend share as competitors bring their own GLP?1 medicines to market, according to company commentary in earnings materials and diabetes conference presentations cited by Bloomberg coverage as of 06/20/2024.

Beyond diabetes and obesity, the Rare Disease segment contributes a stable, albeit smaller, stream of revenue. Products for hemophilia and growth disorders tend to face slower competitive erosion because of specialized indications and complex treatment regimens. However, these therapies are also subject to health technology assessments and price negotiations, especially in European markets where payers closely scrutinize cost?effectiveness data.

Geographically, the United States has become the dominant market for Novo Nordisk’s growth products, particularly GLP?1s. U.S. pricing and reimbursement thus play an outsized role in the company’s margin profile and cash generation. This is relevant for U.S. investors because Novo Nordisk’s American Depositary Receipts trade on the New York Stock Exchange and are widely held in U.S. mutual funds and exchange?traded funds focused on healthcare and large?cap international equities.

Conclusion

Novo Nordisk A/S has transformed from an insulin specialist into a central player in the global obesity and diabetes treatment landscape, with GLP?1 medicines driving much of the recent share price attention and earnings momentum. Strong demand for Ozempic and Wegovy has underpinned revenue growth and made manufacturing capacity and supply chain optimization key operational priorities. At the same time, debates around U.S. pricing, reimbursement and long?term cardiovascular outcomes keep the investment case dynamic and closely watched in policy circles. For U.S. investors following large?cap healthcare and international growth stories, Novo Nordisk’s trajectory in obesity and metabolic disease remains a significant theme but comes with regulatory, competitive and execution?related uncertainties that warrant careful monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.